Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $35.1 million.

  • Avidity Biosciences' Change in Accured Expenses rose 154.49% to $35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 250.68%. This contributed to the annual value of $35.2 million for FY2024, which is 1018.70% up from last year.
  • Latest data reveals that Avidity Biosciences reported Change in Accured Expenses of $35.1 million as of Q3 2025, which was down 25.60% from $47.2 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Change in Accured Expenses peaked at $47.2 million during Q2 2025, and registered a low of -$15.3 million during Q1 2025.
  • For the 3-year period, Avidity Biosciences' Change in Accured Expenses averaged around $9.6 million, with its median value being $4.1 million (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 204.52% in 2023, then soared by 2,314.29% in 2024.
  • Over the past 5 years, Avidity Biosciences' Change in Accured Expenses (Quarterly) stood at $2.2 million in 2021, then skyrocketed by 189.19% to $6.3 million in 2022, then slumped by 40.62% to $3.7 million in 2023, then spiked by 312.75% to $15.4 million in 2024, then spiked by 154.49% to $35.1 million in 2025.
  • Its last three reported values are $35.1 million in Q3 2025, $47.2 million for Q2 2025, and -$15.3 million during Q1 2025.